Identify unmet medical needs and underserved patient groups early on your precision medicine journey. Shorten drug development timelines and reduce costs by leveraging SOPHiA DDM™ Platform to unlock biologically actionable insights from genomic and molecular epidemiology profiles, geographical distribution, and routine genetic testing practices.

**Patient Group Selection**
Understand the size and geographical distribution of your target populations and identify patient subgroups based on biomarker and molecular profiles.

**Biomarker Identification**
Unveil co-occurring and mutually exclusive mutation patterns across diverse patient groups.

**Molecular Epidemiology Insights**
Unveil the genetic alterations associated with disease at the population level.

**Benefits of SOPHiA DDM™ Insights**
- De-risk and expedite your clinical development process by identifying the right targets for drug development.
- Eliminate the guesswork by accessing real-life data from diverse patient populations early in your journey.
- Accelerate enrollment by exploring real-time data from a vast clinical research network spread across 750+ institutions.

Accelerate drug development with SOPHiA DDM™ Insights

Identify the genomic biomarker of interest
Run a retrospective study on SOPHiA DDM™
Run a deeper epidemiology analysis on SOPHiA DDM™
Define the geographic scope of interest
Generate a statistical data insights report

CASE STUDY
SOPHiA DDM™ Insights Enables the Epidemiologic Study of MET Exon 14 Skipping

**MET** alterations are an attractive clinical target in human cancers. However, multiple aspects of its molecular epidemiology remain challenging, particularly the interpretation of variants leading to exon skipping events.

**Key outcomes**

1. SOPHiA DDM™ Insights allowed the accurate detection of **MET** alterations and exon skipping events at the DNA and RNA level.
2. In Europe, 3.2% of cancer patients tested positive for **MET** variants that could lead to ex14 skipping.
3. About 25% of **METex14dels** co-occurred with alterations in other lung cancer-associated genes.

**Tests**

- **MET testing footprint in Europe**
- **METex14 co-occurrence with other oncogenes**

<table>
<thead>
<tr>
<th><strong>Tests</strong></th>
<th><strong>METex14 co-occurrence with other oncogenes</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>N=20,000</td>
<td><strong>KRAS</strong> (N=61)</td>
</tr>
<tr>
<td>N=70+</td>
<td><strong>BRAF</strong> (N=18)</td>
</tr>
<tr>
<td>N=1 Million+</td>
<td><strong>ALK</strong> (N=18)</td>
</tr>
<tr>
<td>N=70+</td>
<td><strong>RET</strong> (N=10)</td>
</tr>
<tr>
<td>N=70+</td>
<td><strong>ROS1</strong> (N=6)</td>
</tr>
</tbody>
</table>


**About SOPHiA GENETICS**

SOPHiA GENETICS (Nasdaq: SOPH) is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM™ platform, a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The SOPHiA DDM™ platform and related solutions, products and services were used by more than 750 hospitals, laboratories, and biopharma institutions globally in 2021.

**Want to learn more?**

Or contact us at: info@sophiagenetics.com

---

The information included in this flyer has been prepared for and is intended for viewing by a global audience. This flyer contains information about products which may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please consult local sales representatives. All product and company names are trademarks™ or registered® trademarks of their respective holders. Use of them does not imply any affiliation with or endorsement by them. SOPHiA DDM™ Insights is for Research Use Only and is not intended for purposes other than research. SOPHiA DDM™ is not for diagnostic, therapeutic, or treatment purposes.